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Summary One hundred and nine samples comprising carcinomas, adenomas, dysplastic, inflamed and normal
mucosa from patients with sporadic colon cancer and ulcerative colitis (UC) were analysed for c-Ki-ras
mutations. DNA was extracted from archival paraffin-embedded material, amplified using the polymerase
chain reaction (PCR) and the PCR products analysed using restriction enzyme digestion. Forty-two per cent
(14/33) of the sporadic carcinoma controls contained Ki-ras codon 12 mutations in contrast to 24% (8/33) of
ulcerative colitis carcinomas. A significantly higher c-Ki-ras mutation rate was observed in rectal carcinomas
(72%) in comparison to colonic carcinomas (28%) in control patients (P<0.04), while the opposite was
observed in UC patients. The difference between the incidence of c-Ki-ras mutations in rectal carcinomas in
UC (9%) and in sporadic rectal carcinomas (72%) was also significant (P<0.01). This lower prevalence rate
and different site distribution of c-Ki-ras mutations in UC carcinomas compared to sporadic carcinomas
suggests that specific genetic differences may underlie the causation of carcinomas arising in these situations.
Colorectal cancer is a well established complication of
ulcerative colitis (UC), with an incidence rate of approxi-
mately 1% (Riddell, 1976). The risk of developing cancer
increases with duration of the disease, with UC patients of
10-20 years having a 20-30-fold elevated rate of cancer
when compared to the general population (Riddell et al.,
1983). A major difference between UC and sporadic carcin-
omas is in their evolution. Carcinomas in UC develop from
areas of flat dysplastic mucosa in contrast to sporadic colo-
rectal carcinomas which arise from adenomas (Morson &
Pang, 1967; Yardley & Keren, 1974). A number of clinical
differences are also apparent between sporadic colorectal car-
cinomas and UC related carcinomas. Tumours occur in a
younger age group in UC with a mean age of onset of 40-42
years, which is much earlier than colorectal cancers without
UC (Devroede et al., 1971). These tumours are often multi-
centric and more evenly distributed throughout the colon
compared to non UC tumours, though in UC, development
of cancer occurs 10 years later in the left colon than in the
transverse and right colon (Greenstein et al., 1979). A higher
percentage of UC related carcinomas present with poorly
differentiated or advanced tumours due to difficulty in diag-
nosis (Riddell et al., 1983). Screening for high risk patients
has been directed towards identifying dysplasia by colono-
scopy and multiple biopsies, though this method is highly
subjective and its justification has been questioned (Glyde,
1990).
Various characteristics of colorectal cancer development in
UC have been investigated with a view to identifying high
risk groups for example mucin and lectin histochemistry
(Fozard et al., 1987), DNA aneuploidy (Fozard et al., 1986)
and expression of blood group antigens (Birnbaum & Menc-
zel, 1985), the c-myc protein (Ciclitra et al., 1987), the K-ras
protein (Michelassi et al., 1987) and TAG-72.3 antigen ex-
pression (Thor et al., 1989). Whilst these techniques have
been able to distinguish between areas of dysplasia and car-
cinoma they have not proven clinically valuable in surveil-
lance programmes for UC.
A number of genetic alterations have been reported to be
associated with sporadic colorectal cancer (Vogelstein et al.,
1988). Among these are mutations in the Ki-ras oncogene
which have been found in 50% of sporadic carcinomas, 58%
of adenomas larger than 1 cm and 9% of adenomas under
1 cm (Vogelstein et al., 1988). Ras mutations appear to occur
at an early stage in the adenoma carcinoma sequence in
colorectal cancer. The ras family of oncogenes are the cellu-
lar homologues of the transforming genes of the Harvey and
Kirsten murine sarcoma viruses. The ras gene encodes a 21
kilodalton protein called p21 which has intrinsic GTPase
activity. This membrane bound protein is thought to be
involved in signal transduction in cellular proliferation and
differentiation pathways. Single point mutations at codons
12, 13 and 61 reduce the GTPase activity of the protein
causing p21 to remain in an active conformation for longer.
The majority of ras mutations in colorectal cancer have been
detected in Kirsten ras, 84% at codon 12 or 13, although a
further 5% have been identified in N-ras codons 12,13 or 61
(Bos, 1989).
While previous studies on colorectal cancer have examined
the incidence of ras mutations in carcinomas arising from
adenomas only two have investigated the occurrence of ras
mutations in UC carcinomas arising from areas of dysplasia.
These two recent studies only examined a small number of
tumours, four and twelve respectively (Meltzer et al., 1990;
Burmer et al., 1990). In this study we confirm that c-Ki-ras
mutations exist in UC carcinomas but at a lower frequency
and with a different site distribution than in sporadic colorec-
tal carcinomas suggesting that specific genetic differences may




We have analysed 109 specimens consisting of 33 tumours
from 26 UC patients comprising 9 Dukes stage A, 11 stage B
and 13 stage C carcinomas, which have been matched for
site, stage and grade with 33 sporadic colorectal carcinoma
controls. Five normal mucosa samples and five non-
dysplastic ulcerative colitis mucosa samples were also
analysed along with eight areas of high grade dysplasia, two
adenomas from UC patients and seven adenomas showing
severe (high grade) dysplasia. All tumours except two were
from formalin-fixed paraffin embedded blocks (up to 24 years
old) obtained from the archives of the pathology departments
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of Leeds and Birmingham Universities. In each case twelve
5 im sections were cut, the first and last sections were stained
with haematoxylin and eosin and only areas containing a
high proportion of neoplastic cells used for DNA extraction.
In 12 cases, nine UC and three sporadic colorectal cancers,
two or more blocks were analysed to identify heterogeneity
within the tumour.
DNA extraction
DNA was extracted from paraffin embedded material using a
method modified from Straus (Straus, 1987; Jackson et al.,
1990). Briefly, ten sections were dewaxed, rehydrated, scraped
into an Eppendorf tube and incubated with 2 mg/ml of Pro-
teinase K (Sigma, Poole, Dorset) and 1% sodium dodecyl
sulphate for 5 days at 37°C. The sample was then extracted
twice with an equal volume of phenol:chloroform:iso-amyl
alcohol (25:24:1) and once with chloroform:iso-amyl alcohol
(24:1). Following ethanol precipitation of the aqueous phase
at -20°C the DNA was recovered by centrifugation, dried
and resuspended in distilled water. The quality of the DNA
was assessed by agarose gel electrophoresis and the quantity
was determined using a TKO-100 minifluorometer (Hoefer
Scientific Instruments) which measures the fluorescence of
Hoescht 33258 (Polysciences) in the presence of DNA.
Polymerase chain reaction (PCR)
The DNA was amplified using PCR to produce a 157bp
fragment containing Ki-ras codons 12 and 13. The primers
were synthesised on an Applied Biosystems DNA Synthesizer
(Pathology Department, University of Leeds). Primer
sequences described by Jiang et al. (1989) contain altered
base pairs which create restriction enzyme sites that allow the
detection of mutations in the first two bases of Kirsten ras
codon 12 or aspartic acid mutations at Ki-ras codon 13. One
gil of the genomic DNA sample was incubated in a total
volume of 50 gil of reaction buffer (50 mM KC1, 10 mM Tris
HCI pH 9, 1.5mM MgCl2, 0.01% gelatin (w/v), 0.1% Triton
X100), containing 0.2mM dATP, dCTP, dTTP and dGTP
(Life Technologies Ltd, Paisley, Scotland), 2.5 units of Taq
DNA polymerase (Promega Corporation, Madison WI,
USA) and 1 mM of each primer. This was overlaid with
mineral oil. The DNA was amplified in a Perkin-Elmer Cetus
thermal cycler by 1 cycle of 94'C for 5 min, 55°C for 48 s and
72°C for 48 s followed by 39 similar cycles with the initial
time at 94'C reduced to 48 s. Once amplification was com-
plete the samples were incubated at 72'C for 10 min to allow
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Figure 1 Diagrammatic representation of fragment sizes created
by restriction enzyme digestion. Tumour DNA which is normal
for Ki-ras codon 12 is cut twice by BstNl, once at the BstNl site
which overlaps codon 12 and once at an internal control site at
the 3' end creating three bands 114bp, 29bp and 14bp in size. If a
mutation is present in either of the first two bases of Ki-ras
codon 12 this destroys the BstN1 site therefore the DNA is cut
only once at the internal control site creating two bands 143bp
and 14bp long. The enzyme Hphl is able to detect a specific
mutation at Ki-ras codon 13 because if the normal glycine is
replaced by aspartic acid due to the substitution of A for G at
the second base of codon 13 at Hphl restriction site is created.
Therefore aspartic acid mutants are cut creating a 114bp and a
43bp band while normal DNA remains uncut.
complete elongation to occur. In each PCR a negative con-
trol was included in which the DNA was omitted. A volume
of 12 gl of the PCR product was then visualised on a 2%
ethidium bromide stained GTG agarose gel (FMC Biopro-
ducts, Rockland ME, USA).
Restriction enzyme digestion
Sixteen gil of the amplified PCR product was digested with
either BstNl or Hphl in a total volume of 25gil under the
conditions recommended by the enzyme suppliers (Boeh-
ringer, Mannheim UK, Lewes, Sussex). The BstNI and Hphl
digestions were incubated at 60°C and 37°C respectively over-
night. The digestion products were analysed on a 3%
ethidium bromide stained Nu sieve agarose gel (FMC Bio-
products). Figure 1 shows a diagrammatic representation of
fragment sizes created by restriction enzyme digestion.
Direct sequencing
Four PCR products were pooled and purified using a Centri-
con 30 column (W R Grace & Co, Danvers MA, USA). Five
hundred ng d.s. DNA was sequenced by the dideoxynucleo-
tide method using Sequenase sequencing kit (USB, Cleve-
land, Ohio) with 35S--dATP (Amersham Int, Aylesbury,
UK) following suppliers recommended conditions. The sam-
ples were run on a 8% polyacrylamide/7 M urea gel for
2-3 h, dried and autoradiographed overnight.
Radioactive PCR
The primers were end-labelled with 35S-y-ATP (Amersham)
using T4 kinase (Life Technologies Ltd) under suppliers
recommended conditions. The radioactive primers were then
used in a 1:3 ratio with cold primers in the PCR reaction
described previously. The radioactive PCR products were
then digested as described above, the gel was dried down and
autoradiographed for 3-4 days.
Results
Genomic DNA from the colon adenocarcinoma cell line
PC/JW (kindly supplied by Dr C. Paraskevas), which is
heterozygous for a Ki-ras codon 12 aspartic acid mutation,
was used as our positive mutant control and genomic DNA
from normal tonsil tissue as our normal control. Direct
sequencing confirmed that the 157bp fragment amplified by
PCR was the required sequence of Ki-ras exon 1 and that the
mutant cell line PC/JW contained a G-*A substitution at one
allele of Ki-ras codon 12 (Figure 2).
The sensitivity of the digestion method was then tested. A
2-fold serial dilution was carried out with the mutant and
normal DNA. Twenty gil of the dilution containing a total of
100 ng of DNA was added to the PCR reaction, amplified,
digested with BstNI and visualised on an ethidium bromide
stained agarose gel. The 143bp mutant band is detectable if
8% of the DNA sample contains a Ki-ras mutation in one
allele (Figure 3, Lane 5). To improve the sensitivity of the
assay we introduced a radioactive label into the PCR. The
above dilution series was carried out using radioactive
primers and the agarose gel was subsequently dried down
and autoradiographed. On the autoradiograph the mutant
band is detectable if 2% of the DNA sample contains a
Ki-ras mutation in one allele (Figure 3, Lane 7). Only the
mutant band is seen on the autoradiograph because the two
labelled primers have both been cleaved off the ends of the
normal band. This improvement in the sensitivity of the
assay also enabled us to obtain results from paraffin embed-
ded material which can be only weakly amplified by PCR
and therefore cannot be visualised on an agarose gel after
digestion (Figure 4, Lane 3).
Eight out of the 33 (24%) tumours from the UC patients
contained ras mutations at Ki-ras codon 12 compared to 141 2 3 4 5 6 7 8 9 10
Figure 2 Direct sequencing of the Ki-ras aspartic acid mutant
cell line PC/JW. An extra band is visible in lane A indicating a G
for A substitution of one allele at Ki-ras codon 12.
Figure 3 Ki-ras codon 12 titration assay. Figure 3a shows the
serial dilution series on an ethidium bromide stained agarose gel,
whilst Figure 3b shows the same series on an autoradiograph.
The top 143bp bands represent the mutant allele while the
bottom 114bp band represents the normal allele on the agarose
gel. Only the normal band is visible on the autoradiograph.
Lanes 1 and 13 123bp ladder marker; Lane 2 Mutant DNA only;
Lanes 3 to 10 A 2-fold serial dilution given 32%, 16%, 8%, 4%,
2%, 1%, 0.5%, 0.25% of mutant DNA to control normal DNA;
Lane 11 Normal DNA only; Lane 12 Uncut DNA.
out of 33 (42%) sporadic colorectal cancer controls; using a
x2 test (P<0.19) this difference did not reach statistical
significance (Table I). A BstNI digest to detect mutations in
either of the first two bases of Ki-ras codon 12 is shown in
Figure 4. Eight areas of high grade dysplasia and two ade-
nomas from UC patients were analysed for Ki-ras mutations.
They were all normal for Ki-ras codon 12 and 13, while 2/7
(28%) adenomas with high grade dysplasia contained Ki-ras
mutations, one in codon 12 and the other in codon 13 (Table
II). Figure 5 shows the codon 13 mutant which contains a G
to A substitution at the second base of codon 13 causing the
normal glycine to be replaced by aspartic acid. Ten non
dysplastic mucosa samples were also screened, five from UC
patients and five from normal patients. These were all normal
at Ki-ras codons 12 and 13 (Table II).
Figure 4 BstNl digest to detect Ki-ras codon 12 mutations.
Lanes 1 and 10 123bp ladder marker; Lanes 2, 4, 5, 7 and 9
tumour samples with ras mutations. Lanes 6 and 8 tumour
samples which are normal for Ki-ras codon 12. Lane 3 A sample
in which the PCR amplification was too weak to be visualised on
an agarose gel after digestion.
Table I Ki-ras mutations in UC carcinomas vs sporadic carcinomas
matched for site and Dukes stage
No of Dukes Ki-ras mutations
Diagnosis tumours Site stage Codon 12 Codon 13
UC Ca 33 Rectum 11 A =9
Sigmoid 6 8 0
Descending 2 B= 11
Sporadic 33 Transverse 2
Ca Ascending 7 C= 13 14 0
Caecum 5
Table II Ki-ras mutations in dysplastic and normal epithelium
Ki-ras mutations
Diagnosis No ofsamples Codon 12 Codon 13
Dysplasia in UC 8 0 0
Adenomas in UC 2 0 0
Sporadic adenomas 7 1 1
Non-dysplastic mucosa 5 0 0
in UC
Normal mucosa 5 0 0
In the sporadic colorectal carcinomas a higher incidence of
c-Ki-ras mutations was observed in the more advanced
tumours with Dukes stage A tumours containing 3/9 (33%),
stage B 5/11 (45%) and stage C 6/13 (46%). The rate of
c-Ki-ras mutations in the UC tumours was slightly lower in
the later stage tumours with Dukes stage A containing 3/9
(33%), stage B 2/11 (18%) and stage C 3/13 (23%).
Multiple samples were analysed from 12 carcinomas to
investigate heterogeneity within the tumour. Only one
tumour was found to be heterogeneous for Ki-ras mutations,
one block contained a ras mutation while two other areas of
the tumour were normal. These samples were repeated using
the more sensitive radioactive method and all three blocks
were found to contain Ki-ras mutations.
In the sporadic carcinomas a higher incidence of c-Ki-ras
mutations was found in rectal tumours (8/11) compared to
colonic tumours (6/22), whilst the opposite was observed in
the UC carcinomas with only one out of 11 rectal tumours
containing mutations compared to 7/22 colonic carcinomas.
This difference in mutation rate between colonic and rectal
carcinomas in sporadic carcinoma patients is statistically
significant using x2 test with a Yates correction (P<0.04),
but not between UC colonic and rectal carcinomas. The
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Figure 5 HphI digest of a Ki-ras codon 13 aspartic acid mutant.
On the autoradiograph the 143bp band represents the mutant
allele which has been cut by Hphl while the top 157bp band
represents the normal allele and/or normal background cells
which have remained uncut.
difference in the incidence of c-Ki-ras mutations between UC
and sporadic rectal tumours is also statistically significant
using x2 test with a Yates correction (P<0.01) though the
colonic carcinomas have a similar incidence rate in both UC
and sporadic carcinoma patients.
Discussion
The origin of UC-associated and sporadic carcinomas differ
in a number of ways, one of the major differences being the
macroscopic appearance of pre-existing dysplasia. Dysplasia
develops in UC in a flat featureless mucosa or raised plaque
in contrast to the polypoid mass or adenoma which gives rise
to sporadic carcinomas (Morson & Pang, 1987; Riddell et al.,
1983).
UC carcinomas are more evenly distributed throughout the
colon compared to sporadic carcinomas, and multiple
tumours are more common in UC in comparison with non-
colitic patients. The most likely explanation for this is the
simultaneous involvement of multiple parts of the colon with
an inflammatory process (MacDermott, 1985). UC carcin-
omas also develop at an earlier age when compared to
sporadic carcinomas probably because of the early age of
onset of UC in many individuals. Patients with onset of UC
in childhood may have had the disease for 20 to 30 years
with its associated increased risk of cancer, before the age of
40 (Devroede et al., 1971). Initially the prognosis of UC
tumours was thought to be worse than sporadic tumours
(van Heerden & Beart, 1980) but later studies controlled for
Duke's stage found the survival rates to be the same (Hughes
et al., 1978). However a higher proportion of UC patients
present with later stage tumours due to the difficulties in
detection (Ritchie et al., 1981). The early detection of colo-
rectal cancer in UC patients is difficult since the symptoms
may mimic those of UC alone. Also the tumours are gener-
ally small and flat and therefore not easily detected by endo-
scopy or radiology (Granqvist et al., 1980). Diagnosis ofhigh
risk patients using colonoscopy and multiple biopsies to iden-
tify areas of dysplasia is highly subjective (Glyde, 1990).
Histological recognition of dysplasia in UC patients is
extremely difficult due to the nature of the disease, since the
presence of inflammatory or regenerative cells complicates
the identification of dysplasia (MacDermott, 1985).
A number of genetic alterations have been identified in
sporadic colorectal cancer, four of the most important iden-
tified so far are allele loss on chromosomes 5, 17 and 18 and
c-Ki-ras gene mutations. Putative genes have been located in
each region of allele loss, the FAP gene on chromosome 5,
though the exact position of the gene has yet to be deter-
mined (Bodmer et al., 1987), the oncogene/tumour suppressor
gene p53 on chromosome 17 and another possible tumour
suppressor gene deleted in colorectal cancer (DCC) gene on
chromosome 18 (Baker et al., 1989; Fearon et al., 1990).
Allele loss on chromosome 5 and c-Ki-ras gene mutations
appear to occur at an early stage in the multistage process
leading to colorectal cancer development, while allele loss on
chromosomes 17 and 18 appears to occur at a later stage
(Vogelstein et al., 1988).
Our finding that 24% of UC carcinomas contain ras muta-
tions in Ki-ras codon 12 is in agreement with recently pub-
lished data by Meltzer et al. (1990) and Burmer et al. (1990)
that ras mutations occur at a lower rate in UC carcinomas
compared to sporadic colorectal carcinomas. These two
recent studies only analysed a small number of samples and
were not properly matched for stage and site with sporadic
colorectal carcinoma controls. Meltzer et al. examined four
UC carcinomas, one of which contained a Ki-ras mutation
(25%), they also identified ras mutations in 2/6 (33%) areas
of high grade dysplasia. Burmer et al. analysed a slightly
higher number of UC carcinomas and found 1/12 (8%)
contained a Ki-ras mutation, also one of the 12 (8%) areas
of high grade dysplasia examined contained ras mutations.
Overall the lower prevalence indicates that c-Ki-ras muta-
tions do not play such an important- role in the dysplasia-
carcinoma sequence in UC patients as in sporadic carcinomas
and that different genetic alterations might occur in this
process. Since we have limited our study to screening for
mutations in c-Ki-ras at codons 12 or 13 which accounts for
the majority of ras mutations identified in sporadic colorectal
cancer, it is possible this lower prevalence rate found in UC
cancers may be accounted for by different ras mutations
occurring in a different codon or Harvey or N-ras.
Since only half of the sporadic colorectal carcinomas con-
tain c-Ki-ras mutations it is possible that the other 50% may
share with UC carcinomas an unidentified genetic abnor-
mality which is complementary to the ras gene mutations.
Further investigation is required to identify whether the later
genetic changes in colorectal cancer, for example allele loss
on chromosomes 17 and 18, play a role in the development
of UC carcinomas.
We found no statistical difference in the prevalence of
c-Ki-ras mutations with increasing stage, although in the
sporadic carcinomas the prevalence increased slightly with
increasfng stage. In UC carcinomas the opposite was observ-
ed with the later Duke's stage B and C tumours containing a
slightly lower number with mutations than the stage A
tumours. In both UC and sporadic tumours a third of the
Dukes stage A tumours contained c-Ki-ras mutations.
This study has shown a difference in the c-Ki-ras mutation
rate related to site distribution of the tumours. A statistically
higher proportion with c-Ki-ras mutations was found in rec-
tal tumours (72%) compared to colonic tumours (28%) in
sporadic cases (P<0.04), these results are similar to pre-
viously published results by Delattre et al. (1989). In con-
trast, in UC tumours a higher rate of c-Ki-ras mutations was
found in colonic tumours (32%) compared to rectal tumours
(9%), though this did not reach statistical significance
(P<0.31). The prevalence rate in colonic tumours was178 S.M. BELL et al.
similar in both UC (32%) and sporadic tumours (27%). The
c-Ki-ras mutation rate in rectal sporadic tumours (72%) was
eight times that found in the UC carcinomas (9%), this
difference is statistically significant (P<0.01).
Our study has found no heterogeneity in the 12 cases
where more than one area of tumour was examined. One
case initially looked as though it was heterogenous, but after
further analysis using the more sensitive radioactive method
all three blocks were found to contain Ki-ras mutations. By
including a radiolabel in our PCR reaction we have increased
the sensitivity of the assay 4-fold allowing the identification
of ras mutations if ) 2% of the DNA sample contains a
Ki-ras codon 12 mutation in one allele. Thus c-Ki-ras muta-
tions, like p53 expression (Scott et al., 1990), fail to show
marked heterogeneity unlike grosser abnormalities found in
these tumours such as DNA aneuploidy (Quirke et al., 1987).
The lower prevalence of c-Ki-ras mutations found in the
dysplasia-carcinoma sequence in UC when compared to the
adenoma-carcinoma sequence- in sporadic colorectal carcin-
omas is similar to the different pattern of ras mutations
shown by papillary and fbllicular thyroid carcinomas. Wright
et al. (1989) found 3/17 (17%) of papillary carcinomas
(which classically arise de novo), contained ras mutations
compared to 8/15 (53%) of follicular carcinomas which arise
through an adenoma-carcinoma sequence; this difference is
statistically significant (2= 4.95 P<0.05). The difference in
the prevalence of ras mutations found between carcinomas
arising from dysplasia as opposed to origin from adenomas
in both colorectal and thyroid tumours may also become
apparent in other tumour systems, and suggests that molec-
ular changes may underlie morphological abnormalities.
In conclusion, our study indicates that there appears to be
genetic differences between sporadic and UC associated colo-
rectal carcinomas. This study also shows that it is not possi-
ble to use c-Ki-ras codon 12 and 13 mutations for screening
purposes to identify UC patients with a high risk of develop-
ing cancer and other molecular abnormalities must be
sought.
This work was supported by the Yorkshire Cancer Research Cam-
paign. We would like to thank Miss J. Hamblin for typing the
manuscript.
References
BAKER, S.J., FEARON, E.R., NIGRO, J.M. & 9 others (1989). Chromo-
some 17 deletions and p53 gene mutations in colorectal carcin-
omas. Science, 2A4, 217.
BIRNBAUM, D. & MENCZEL, J. (1985). ABO blood group distribu-
tion in ulcerative and malignant diseases of the gastrointestinal
tract. Gastroenterology, 37, 210.
BODMER, W.F., BAILEY, C.J., BODMER, J. & 10 others (1987). Local-
ization of the gene for familial adenomatous polyposis on
chromosome 5. Nature, 328, 614.
BOS, J.L. (1989). Ras oncogenes in human cancer: a review. Cancer
Res., 49, 4682.
BURMER, G.C., LEVINE, D.S., KULANDER, G.B., HAGGITT, R.C.,
RUBIN, C.E. & RABINOVITCH, P.S. (1990). C-Ki-ras mutations in
chronic ulcerative colitis and sporadic colon carcinoma. Gastro-
enterology, 99, 416.
CICLITRA, P.J., MACARTNEY, J.C. & EVANS, G. (1987). Expression
of c-myc in non-malignant and pre-malignant gastrointestinal
disorders. J. Pathol., 151, 293.
DELATTRE, O., LAW, D.J., REMVIKOS, Y. & 7 others (1989). Multiple
genetic alterations in distal and proximal colorectal cancer.
Lancet, ii, 353.
DEVROEDE, G.J., TAYLOR, W.F., SAVER, W.G., JACKMAN, R.J. &
STICKLER, G.B. (1971). Cancer risk and life expectancy of child-
ren with ulcerative colitis. N. Engi. J. Med., 285, 17.
FEARON, E.R., CHO, K.R., NIGRO, J.M. & 8 others (1990). Identi-
fication of a chromosome 18q gene that is altered in colorectal
cancer. Science, 247, 49.
FOZARD, J.B., QUIRKE, P., DIXON, M.F., GILES, G.R. & BIRD, C.C.
(1986). DNA aneuploidy in ulcerative colitis. Gut, 27, 1414.
FOZARD, J.B., DIXON, M.F., AXON, A.T.R. & GILES, G.R. (1987).
Lectin and mucin histochemistry as an aid to cancer surveillance
in ulcerative colitis. Histopathology, 11, 385.
GRANQVIST, S., GABRIELSSON, N., SUNDELIN, P. & THORGEIRS-
SON, T. (1980). Precancerous lesions in the mucosa in ulcerative
colitis. A radiographic, endoscopic, and histopathologic study.
Scand. J. Gastroent., 15, 289.
GREENSTEIN, A.J., SACHAR, D.B. & PUCILLO, A. (1979). Cancer in
universal and left-sided ulcerative colitis: clinical and pathological
features. M. J. Sinai. J. Med., 45, 25.
GLYDE, S. (1990). Screening for colorectal cancer in ulcerative colitis:
dubious benefits and high costs. Gut, 31, 1089.
HUGHES, P.G., HALL, T.J. & BLOCK, C.E. (1978). Prognosis of car-
cinoma of the colon and rectum complicating ulcerative colitis.
Surg. Gynec. Obstet., 146, 46.
JACKSON, D.P., LEWIS, F.A., TAYLOR, G.R., BOYLSTON, A.W. &
QUIRKE, P. (1990). Tissue extraction of DNA and RNA and
analysis by the polymerase chain reaction. J. Clin. Pathol., 43,
3499.
JIANG, W., KAHN, S.M., GUILLEM, J.G., LU, S.D. & WEINSTEIN, I.B.
(1989). Rapid detection of ras oncogenes in human tumours:
applications to colon, esophageal and gastric cancer. Oncogene, 4,
923.
MACDERMOTT, R.P. (1985). Review of clinical aspects of cancer of
the colon in patients with ulcerative colitis. Dig. Dis. Sci., 30,
1145.
MELTZER, S.J., MANE, S.M., WOOD, P.K. & 6 others (1990). Activa-
tion of C-Ki-ras in human gastrointestinal dysplasias determined
by direct sequencing of polymerase chain reaction products.
Cancer Res., 50, 3627.
MICHELASSI, F., LAITHNER, S., LUBIENSKI, M. & 4 others (1987).
Ras oncogene p21 levels parallel malignant potential of different
human colonic benign conditions. Arch. Surg., 122, 1414.
MORSON, B.C. & PANG, L.S.C. (1967). Rectal biopsy as an aid to
cancer control in ulcerative colitis. Gut, 8, 423.
QUIRKE, P., DIXON, M.F., CLAYDEN, A.D. & 4 others (1987). Prog-
nostic significance of DNA aneuploidy and cell proliferation in
rectal adenocarcinomas. J. Pathol., 151, 285.
RIDDELL, R.H. (1976). The precarcinomatous phase of ulcerative
colitis. In Current Topics Pathol., 23, Morson, B.C. (ed.) p. 179,
Springer, Berlin.
RIDDELL, R.H., GOLDMAN, H., RANSOHOFF, D.F. & 9 others
(1983). Dysplasia in inflammatory bowel disease: standardized
classification with provisional clinical applications. Human. Path.,
14, 931.
RITCHIE, J.K., HAWLEY, P.R. & LENNARD-JONES, J.E. (1981). Prog-
nosis of carcinoma in ulcerative colitis. Gut, 22, 752.
SCOTT, N., SAGAR, P., STEWART, J., BLAIR, G.E., DIXON, M.F. &
QUIRKE, P. (1991). p53 in colorectal cancer: clinicopathology cor-
relation and prognostic significance. Br. J. Cancer, 63, 317-319.
STRAUS, W.M. (1987). Preparation of genomic DNA from mamma-
lian tissues. In Current Protocols in Molecular Biology. Ausubel et
al. (ed.) p. 2.2.1. Green.
THOR, A., ITZKOWITZ, S.H., SCHLOM, J., KIM., S.Y. & HANAUER, S.
(1989). Tumor-associated glycoprotein (TAG-72) expression in
ulcerative colitis. Int. J. Cancer, 43, 810.
VAN HEERDEN, J.A. & BEART, R.W. (1980). Carcinoma of the colon
and rectum complicating chronic ulcerative colitis. Dis. Colon
Rectum, 231, 155.
VOGELSTEIN, B., FEARON, E.R., HAMILTON, S.R. & 7 others (1988).
Genetic alterations during colorectal tumour development. N.
Engl. J. Med., 319, 525.
WRIGHT, P.A., LEMOINE, N.R., MAYALL, E.S. & 4 others (1989).
Papillary and follicular thyroid carcinomas show a different
pattern of ras oncogene mutation. Br. J. Cancer, 60, 576.
YARDLEY, J.H. & KEREN, D.F. (1974). Precancer lesions in ulcerative
colitis. Cancer, 34, 835.